Working to improve the lives of those with this rare condition.

Dermatomyositis (DM) is a rare inflammatory skin and muscle disease caused by the immune system attacking the body’s own cells. Patients with DM often have skin rashes, calcinosis or calcium deposits under the skin, muscle weakness and other complications, such as lung disease and difficulty swallowing. DM affects about 25,000 adult and 6,000 juvenile patients in the United States. Despite important advancements in care over the last 20 years, there are few approved treatments for DM, and patients may have difficulty controlling their disease.

There’s no cure for dermatomyositis, but treatment can improve the skin, and muscle strength and function. The earlier treatment is started, the more effective it is, leading to fewer complications such as difficulty swallowing, breathing problems, and aspiration pneumonia. Even though it’s better to start treatment earlier rather than later, current treatments, including corticosteroids and immunosuppressive drugs, have demonstrated limited efficacy and serious side effects.

We recently initiated a Phase 2 clinical trial with IMO-8400 in patients with dermatomyositis.

More information about dermatomyositis and other forms of myositis is available on The Myositis Association’s website.

For more information on this study or study site locations, go to U.S. FDA Clinical Trial Registry Site, contact Idera at clinicaltrials@iderapharma.com, or visit Idera’s Clinical Trials site at Idera’s Clinical Trials Website.

Pioneer 2

  • Our Approach

    Learn more about our unwavering dedication to defeating certain cancers and rare diseases.